	US 11,692,009 B2
	IL-2alpha receptor subunit binding compounds
William J. Dower, Menlo Park, CA (US); Michael C. Needels, Menlo Park, CA (US); Ronald W. Barrett, Menlo Park, CA (US); Alice V. Bakker, Menlo Park, CA (US); and Steven E. Cwirla, Menlo Park, CA (US)
Assigned to MEDIKINE, INC., Menlo Park, CA (US)
Filed by MEDIKINE, INC., Menlo Park, CA (US)
Filed on Jan. 5, 2022, as Appl. No. 17/569,117.
Application 17/569,117 is a continuation of application No. 16/890,749, filed on Jun. 2, 2020, granted, now 11,248,025.
Claims priority of provisional application 62/856,305, filed on Jun. 3, 2019.
Prior Publication US 2022/0119453 A1, Apr. 21, 2022
Int. Cl. A61K 38/00 (2006.01); C07K 7/08 (2006.01)

CPC C07K 7/08 (2013.01) [A61K 38/00 (2013.01)]

20 Claims

1. An IL-2Rα ligand, wherein the IL-2Rα ligand comprises an amino acid sequence of Formula (20a) (SEQ ID NO: 235) or Formula (20b) (SEQ ID NO: 236), wherein the IL-2Rα ligand binds to the human IL-2Rα subunit with an IC₅₀of less than 100 μM:

-X³-X⁴-X⁵-X⁶-X⁷-X⁸-X⁹-X¹⁰-X¹¹-X¹²- (20a)

-X¹-C-X³-X⁴-X⁵-X⁶-X⁷-X⁸-X⁹-X¹⁰-X¹¹-X¹²-C-X¹⁴- (20b)

wherein,

X¹is W;

X²is C;

X³is selected from F, I, L, M, V, W, and Y;

X⁴is G;

X⁵is Q;

X⁶is P;

X⁷is L;

X⁸is selected from F, I, L, M, V, W, and Y;

X⁹is R;

X¹⁰is selected from H, N, Q, F, I, L, M, V, W, and Y;

X¹¹is G;

X¹²is S;

X¹³is C; and

X¹⁴is K.